SCHEMBL2858005

SCHEMBL2858005

FC(F)(F)c1ccc(-c2cnccn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.55
CYP2D6 P10635 1/20 0.47
CYP19A1 P11511 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
CCNB2 O95067 1/20 0.46
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
CCNB3 Q8WWL7 1/20 0.46
NPY5R Q15761 1/20 0.45
NPC1 O15118 1/20 0.45
KDM1A O60341 1/20 0.43
MAOB P27338 1/20 0.43
TOP1 P11387 1/20 0.43
TRPV1 Q8NER1 1/20 0.42
S1PR1 P21453 1/20 0.42
ABL1 P00519 1/20 0.42
BCR P11274 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11541937 0.83 CYP2D6 (0.60) CYP2D6CYP19A1CYP2C9CYP2C19NPY5R
SCHEMBL12632461 0.81 KIF11 (0.55) KIF11CYP2D6CYP19A1CYP2C9CYP2C19
SCHEMBL17619985 0.79 TRPV4 (0.47) CYP2D6CYP19A1CYP2C9CYP2C19ABL1
SCHEMBL30238069 0.79 NPSR1 (0.43) KIF11NPC1KDM1AMAOBTRPV1
SCHEMBL29683245 0.79 CYP19A1 (0.52) CYP2D6CYP19A1CYP2C9CYP2C19NPC1
SCHEMBL17246864 0.79 CYP19A1 (0.52) CYP2D6CYP19A1CYP2C9CYP2C19NPC1
SCHEMBL2406368 0.79 IDO1 (0.54) KIF11NPY5RKDM1AMAOBABL1
SCHEMBL5992577 0.78 CYP2D6 (0.51) CYP2D6CYP19A1CYP2C9CYP2C19CCNB2
Hydrochloric Acid SCHEMBL28429357 0.78 IDO1 (0.53) KIF11NPY5RKDM1AMAOBABL1
SCHEMBL4717978 0.77 KIF11 (0.40) KIF11CCNB2CDK1CCNB1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107709312-A Novel antimalarial drug 开普敦大学 2018-02-16 CN claimed
CN-110407816-B Compound, application and device adopting compound 清华大学 2021-08-13 CN disclosed
US-20200275655-A1 PYRIDINIUM SALT AND PEST CONTROL AGENT NIPPON SODA CO., LTD. (JP) 2020-09-03 US disclosed
CN-108026050-A NOVEL COMPOUNDS AS ROR GAMMA MODULATORS 格兰马克药品股份有限公司 2018-05-11 CN disclosed
CN-107709312-A Novel antimalarial drug 开普敦大学 2018-02-16 CN disclosed
CN-107078217-A Semiconductor composition comprising inorganic semiconductor material and organic bond 默克专利股份有限公司 2017-08-18 CN disclosed
EP-2013171-B1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE MERCK SHARP & DOHME (GB) 2013-05-15 EP disclosed
US-8389547-B2 Piperidines and related compounds for the treatment of Alzheimer's disease MERCK SHARP & DOHME LLC 2013-03-05 US disclosed
US-20100048623-A1 PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-02-25 US disclosed
EP-1805141-B1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (GB) 2010-01-20 EP disclosed
US-7638629-B2 Piperidines and related compounds for treatment of alzheimer's disease Merck Sharp & Dohme Ltd, (GB) 2009-12-29 US disclosed
EP-2013171-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE Merck Sharp & Dohme Limited (GB) 2009-01-14 EP disclosed
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LTD. (GB) 2008-01-24 US disclosed
WO-2007125364-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2007-11-08 WO disclosed
EP-1805141-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LTD. (GB) 2007-07-11 EP disclosed
WO-2006043064-A1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease PSEN1, PSEN2, APP KIF11 4413/4885CYP2D6 3883/4885CYP19A1 2824/4885
US-20200275655-A1 PYRIDINIUM SALT AND PEST CONTROL AGENT PRDX1, KCNQ5, KCNQ1 KIF11 3339/4885CYP2D6 776/4885CYP19A1 3249/4885
US-20100048623-A1 PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, PSEN1, BACE2 KIF11 4104/4885CYP2D6 2952/4885CYP19A1 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.